T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo.

Pharmaceutics · 2023 · PMC10054149 · PMID 36986589

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

This is consistent with the highly significant reduction induced in BM leukemic burden after nanotoxin treatment in vivo, using the same mechanism of action as ITs that kill non-dividing cells by inhibiting eEF-2 and protein translation synthesis [ 57 ].

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.